<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

3 min read

SMISS 2024 - MIS Spine Continues to Grow

By Erin Dorgan on 10/8/24 9:28 AM

SmartTRAK takes a look at trends impacting the MIS Spine market.

The seventeenth Society of Minimally Invasive Spine Surgery (SMISS) Annual Forum was held in Las Vegas, Nevada, from September 5 to 7. It is the only US-based spine meeting dedicated to minimally invasive surgery (MIS). At this year’s meeting, the presenters focused on “innovate, adapt and evolve.”
 

In this article, SmartTRAK highlights key presentations and the latest trends from SMISS 2024 affecting the Spine Market. This includes what challenges still exist for MIS transforaminal lumbar interbody fusion (TLIF) procedures, considerations for surgeons learning the prone transpsoas (PTP) approach, indication expansion opportunities for cervical disc replacement (CDR) and factors that could disrupt the market for spine surgeons. SmartTRAK estimates these trends will contribute to the US MIS market 5-year CAGR of +7.0% by 2028. 

The topics covered include:

  • New Technologies Help Advance MIS TLIF Procedures
    • SmartTRAK estimates that MIS posterior procedures will reach 88K in 2028E, and over half of the interbody procedures are ... (read more)
  • Lateral Lumbar Interbody Procedures Growing in Mid-Single Digits
    • One of the fastest growing segments of the MIS Spine Market is Lateral Lumbar Interbody Fusion, which SmartTRAK estimates is growing with a 5-year CAGR of ... (read more)
  • Cervical Disc Replacement Indications Poised to Expand
    • SmartTRAK estimates that the CDR market is one of the fastest growth markets in Spine, with a projected 5-year revenue ... (read more)
  • ‘Innovator’s Dilemma’ Could Disrupt the Spine Market for Surgeons
    • Concluding the meeting with his presidential address, Sheeraz Qureshi, MD, MBA, Co-Chief of Hospital of Special Surgery Spine and an Attending Orthopedic Surgeon at HSS, shared his vision of the future of the Spine Market with ... (read more)

Click the button below to download and read the complete "SMISS 2024 - MIS Spine Continues to Grow" perspective article by Erin Dorgan, SmartTRAK Sr Analyst, Spine and Orthobiologics.

Topics: Spine
Continue Reading
4 min read

Reimbursement Changes: Wound Dressings Under Threat in Germany

By Anikó Szekér on 10/1/24 9:30 AM

In an interview with SmartTRAK, Dr. Willi Schnorpfeil, an expert in reimbursement strategies, offers a comprehensive overview of the regulatory changes for advanced wound care products in Germany, which pose a potential threat to both market stability and patient care.

In an interview with SmartTRAK, Dr. Willi Schnorpfeil, managing partner of Value & Dossier and Reimbursement Specialist, provides insights into the scope, impact and potential future developments of changes in Germany’s reimbursement landscape, specifically concerning the Advanced Wound Dressing Market. Dr. Schnorpfeil highlights the challenges faced by the industry in meeting new evidence requirements and the possible implications for patient outcomes. This conversation sheds light on the complex regulatory environment in Germany and its broader implications for the healthcare sector across Europe.

Click on the video below to listen to SmartTRAK’s interview with Dr. Schnorpfeil (24:18 minutes), which was recorded on August 22. A link to download the complete transcript of the interview is also provided below. 

 

Topics: Wound Care wound
Continue Reading
2 min read

Trends and Developments in Spine Enabling Technologies at NASS 2024

By Thomas Wallick on 9/24/24 9:36 AM

SmartTRAK is attending the upcoming North American Spine Society (NASS) meeting being held Sept. 25-28 in Chicago, Our team can't wait to see all of our colleagues at the premier meeting for the spine market. To help you get ready for the meeting, in the following video, Elise Wolf, SmartTRAK's VP & GM of Orthopedics and Digital, reviews the latest trends and developments in the Spine Enabling Technologies market.



If you would like to see more of what SmartTRAK has to offer in spine coverage, including some of our recent articles on the trends and developments in the Spine Enabling Technologies market, or if you would like to meet with us at NASS 2024 in Chicago,  just click the button below.

Continue Reading
2 min read

NASS 2024: Bone Replacement Developments to Know Before You Go

By Thomas Wallick on 9/23/24 1:35 PM

SmartTRAK is attending the upcoming North American Spine Society (NASS) meeting being held Sept. 25-28 in Chicago, and we can't wait to see all of our colleagues at the premier meeting for the spine market. To help you get ready for the meeting, Erin Dorgan, SmartTRAK Senior Analyst, Spine, has recorded this video update with an overview of the bone replacement products and companies to watch at NASS 2024.



If you would like to see more of what SmartTRAK has to offer in spine coverage and the bone replacement market, including some of our recent articles, or meet with us at NASS 2024,  just click the button below.

Continue Reading
2 min read

ASPN 2024: Research and Innovation in Interventional Pain

By Anne Staylor on 9/18/24 9:30 AM

SmartTRAK reports the latest research and innovation in interventional pain management from ASPN 2024. 

Interventional pain management is rapidly evolving. Practitioners are expanding the tools in their toolbox beyond traditional pain therapies to offer patients a wider range of new and innovative treatment options in spinal cord stimulation (SCS), peripheral nerve stimulation (PNS), minimally invasive spine and radiofrequency ablation as well as regenerative and restorative therapies.  

In this article,  SmartTRAK  highlights the latest research and innovation in interventional pain management from the American Society of Pain & Neuroscience (ASPN) Annual Conference, held July 11-14  in Miami, FL. The ASPN meeting has grown exponentially over the last several years and is a reflection of the growing interest in providing more treatment options to patients with chronic intractable pain. (See also  SmartTRAK’s  interview with ASPN Chairman Tim Deer, MD,  ASPN 2024: Evolving Ideas into Innovation and Practice .)
 
Among the many topics covered in detail in this informative article are:
 

Spinal Cord Stimulation

  • Correlating Neurophysiological Data to Pain and Treatment Success
  • FAST US Real-World Data
  • Remote SCS Management
  • Data Supporting Expanded Indications
    • Nonsurgical Back Pain
    • Painful Diabetic Neuropathy
    • Nociceptive Pain

Peripheral Nerve Stimulation

  • Craniofacial, Head/Neck Pain
  • Comfort PNS Devices
  • Next Generation PNS Devices

Minimally Invasive Spine

  • Basivertebral Nerve Ablation (BVNA)
  • Minimally Invasive SI Joint Fusion
  • Lumbar Decompression for Lumbar Spinal Stenosis

Regenerative and Restorative Medicine

  • Intradiscal Therapy

Click the button below to download and read the complete "ASPN 2024: Research and Innovation in Interventional Pain" Market Outlook article by Anne Staylor, SmartTRAK Executive Editor, VP & GM of Neuro Therapies.

 

Continue Reading
2 min read

NASS 2024: What to Know Before You Go

By Thomas Wallick on 9/17/24 9:35 AM

SmartTRAK is attending the upcoming North American Spine Society (NASS) meeting being held Sept. 25-28 in Chicago, and we can't wait to see all of our colleagues at the premier meeting for the spine market. To help you get ready for the meeting, Erin Dorgan, SmartTRAK Senior Analyst, Spine, has recorded a video update with the trends, key players and innovations to know before the show.



If you would like to see more of what SmartTRAK has to offer in spine market coverage, including some of our recent articles, or meet with us at NASS 2024,  just click the button below.

Continue Reading
2 min read

Checking the Pulse of the Foot & Ankle Market

By Natasha Weeks on 9/11/24 9:30 AM

SmartTRAK takes a look at recent trends impacting the Foot & Ankle market.

As the first half of 2024 closes, SmartTRAK has observed a continued investment in the hallux valgus space. New implants and innovative instrumentation for hallux valgus procedures continue to push this segment to the forefront of the elective foot and ankle fixation space. While hallux valgus is front of mind for fixation, arthroplasty is also making waves as SmartTRAK continues to monitor toe replacement and advancements in ankle replacement.

As companies close out Q2 earnings, SmartTRAKcoverage has indicated slightly mixed results in the Extremities space. In this downloadable article, SmartTRAK examines recent trends impacting the Foot and Ankle market. including what's happening with hallux valgus procedures, which shows no signs of slowing down, and puts a spotlight on arthroplasty in the Foot &  Ankle segment

Click the button below to download and read the complete "Checking the Pulse of the Foot & Ankle Market" article by Natasha Weeks, SmartTRAK Managing Editor/Sr. Analyst Trauma & Extremities.

Continue Reading
2 min read

HealthPoint Capital Investor Day 2024: What to Know Before You Go

By Thomas Wallick on 9/9/24 6:16 PM

The 2024 HealtThe 2024 HealthpointCapital Investor Day is taking place on Friday, Sept. 13 in Las Vegas, and SmartTRAK will be there. Elise Wolf, SmartTRAK VP and GM of Orthopedics, has a new video update with everything you need to know before you go.



If you'd like to see more of what SmartTRAK has to offer in orthopedic coverage, including some of our recent articles on extremities, spine, enabling tech and total joints, just click the button below.

Continue Reading
2 min read

AOFAS 2024: What to Know Before You Go

By Thomas Wallick on 9/6/24 12:39 PM

SmartTRAK is attending the upcoming American Orthopaedic Foot & Ankle Society Meeting (AOFAS), being held Sept. 11-14  in Vancouver, and we can't wait to see all of our colleagues at the premier meeting for foot and ankle. To help you get ready for the meeting, SmartTRAK's GM of Trauma & Extremities, Natasha Weeks, has recorded a video update with the trends, key players and innovations to know before the show.




If you'd like to meet with Natasha in Vancouver or just read more of SmartTRAK's coverage of the Foot & Ankle market, visit SmartTRAK Foot and Ankle Central.

Continue Reading
3 min read

Medtronic: Transforming DBS Therapy - An Interview with Amaza Reitmeier

By Anne Staylor on 9/4/24 9:45 AM

Amaza Reitmeier, Medtronic’s VP and GM of Brain Modulation, discusses the company’s recent FDA approvals for asleep DBS and expanded MRI labeling, and provides an update on adaptive DBS in an interview with SmartTRAK. 

In an interview with SmartTRAK, Medtronic’s Amaza Reitmeier, vice president and general manager of Brain Modulation, discusses the company’s recent news in deep brain stimulation (DBS), including FDA approval for asleep DBS and MRI expanded labeling that allows patients to undergo additional scan time. She also provides an update on adaptive DBS (aDBS) and the ADAPT-PD trial, which is expected to support the global regulatory submissions to commercialize aDBS in patients with PD.  Medtronic recently filed for US FDA approval of aDBS.

Click on the following video to listen to the interview (14:32 minutes). A link to download a complete transcript of the interview is also provided below.
 


Interview Transcript

SmartTRAK: Hey everybody. Anne Staylor here with SmartTRAK. Today I get to talk to Amaza Reitmeier, the vice president and general manager of Brain Modulation at Medtronic. Hey Amaza, thanks for talking with me.

Amaza Reitmeier: Hi, Anne. Great to see you.

I know that you have some big news around DBS. You guys are advancing pretty quickly. The latest news involves FDA approval for asleep vs awake DBS, MRI expanded labeling, and then maybe you could give me an update on some other aspects of the adaptive DBS. So let's get started.

AR: Fantastic.

What is the significance? Talk a little bit about the FDA approval for asleep vs awake DBS, and why is that important? A lot of people are doing that. Just talk a little bit about the significance of that and what it means for Medtronic.

AR:
Thank you, Anne. Well, first and foremost, you know from our prior conversations that we're very focused on the patient and making sure that patients have the best options available to them. While you're right that asleep DBS has been being done for years, it's actually been contraindicated in our labeling. The original labeling for DBS, which was established decades ago, required test stimulation to confirm that the therapy was working. But we also know that ...

Click the button below to download and read the full transcript of the SmartTRAK perspective article "Transforming DBS Therapy - An Interview with Amaza Reitmeier" conducted by Anne Staylor, SmartTRAK's Executive Editor and VP & GM of Neuro Therapies. Download the Transcript

Continue Reading
  • There are no suggestions because the search field is empty.

Follow Us on Social Media

Recent Articles